Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Mangoceuticals, Inc. ( (MGRX) ).
On March 24, 2025, Mangoceuticals, Inc. entered into an agreement with Navy Wharf for exclusive licensing rights to a nutraceutical product. However, on July 30, 2025, both parties agreed to terminate the agreement without incurring material penalties, and Navy Wharf canceled all previously issued shares. Additionally, on July 29, 2025, a warrant holder exercised options to purchase 198,000 shares of common stock, raising $297,000.
More about Mangoceuticals, Inc.
Mangoceuticals, Inc. operates in the nutraceutical industry, focusing on products designed to manage blood glucose and Hemoglobin A1c levels, marketed under the brand Diabetinol® in the United States and Canada.
Average Trading Volume: 170,733
Technical Sentiment Signal: Sell
Current Market Cap: $18.2M
Find detailed analytics on MGRX stock on TipRanks’ Stock Analysis page.